Jeff Golini, CEO and executive scientist, All American Pharmaceutical & Natural Foods Corporation (AAP), announced today that an upcoming 2014 KarboLyn® clinical study will be headed by Dr. Thomas Harman, a former Family Medicine Department chairman at the Mayo Clinic in Rochester, Minnesota. The study entitled: A Placebo-Controlled Double-Blind Pilot Study: Blood Sugar Response to KarboLyn® or a Glucose Drink during Aerobic Activity, will examine the impact this novel, proprietary homopolysaccharide mixture has on glucose response in normal, and pre-diabetic, adults during aerobic activity.
The National Diabetes Education Program, in conjunction with the National Institutes of Health (NIH), reports approximately 79 million adults aged 20 and older have prediabetes. Research has shown that by losing weight and increasing physical activity people can prevent or delay prediabetes from progressing to diabetes.
KarboLyn® supports aerobic activity
KarboLyn® was initially designed for the elite athlete who wants to effectively muscle-load glucose before a workout and avoid ‘burn-out’ or ‘crash’ during high-intensity aerobic activity. “We already know KarboLyn® behaves somewhat differently than the standard ‘sugar solution’ when it is being consumed by normal adults before athletic workouts,” explained Golini. In addition to the glucose response in these normal people during aerobic activity, it may also have a unique impact on the pre-diabetics and hence other uses that is also what this research is going to tell us.” The study will be fielded this summer with healthy and pre-diabetic adults.
All American Pharmaceutical has an unwavering commitment to the pursuit of excellence in continued clinical research and product production. “We are committed to more research and development in the coming months and years. Our pipeline of products is strategically poised to impact a number of fields in the 21st century,” said Golini. “We are slowly ramping up research geared toward examining the impact of our proprietary products on various physiological conditions from the athletic industry to healthcare.”
“Today’s athletes come in all shapes and physiological types,” Golini affirmed. We want to know how our products are going to impact a broad range of users.”